Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein
(NS5A) resistance-associated variants. Daclatasvir (60mg/day) and asunaprevir (100 mg twice
daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks will be prescribed.
Phase:
Phase 3
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan